Original news and analysis on international IP policy
As staff strikes continue and the European Patent Office's Administrative Council prepares for what could be a contentious 11 December meeting, opinions are split over the effect of the turmoil on the office's role in Europe's unitary patent.
The 29th Session of the Standing Committee on Copyright and Related Rights at the World Intellectual Property Organization is currently underway. On the agenda, inter alia, will be discussions on Limitations and Exceptions to Libraries, Archives and Educational, Teaching and Research Institutions. Against the backdrop of the success with the Marrakesh Treaty, the trajectory looks set for these further exceptions and limitations to succeed.
A seminar on innovation and access to medicine last week examined the issue of access to hepatitis C treatment, looking at the HIV/AIDS path. Voluntary licences, such as the one entered by Gilead for its hepatitis drugs, have been applauded but such licences often do not cover middle-income countries, which are home to the bulk of hepatitis C patients, and whose poor populations remain unable to access treatment.
Last week’s United Nations draft report for the post-2015 sustainable development goals under negotiation calls for continued progress toward sweeping improvements in the lives of all people and the health of the planet, including ensuring that intellectual property rights are respected but do not get in the way.
Gender differences persist in the field of intellectual property, but there are signs of change, and new proposals are emerging for bringing greater balance, a US professor told a gathering at the World Intellectual Property Organization this week.
The 2014 edition of an independent ranking of leading pharmaceutical companies' efforts to help developing countries released today found new initiatives undertaken in the past two years. But it said corruption and insufficient disclosure of existing patents continue to plague the industry.
Public health activists and others have been watching closely in recent months as United States government and industry officials meet steadily and intensively with Indian counterparts to press change in that country's intellectual property policy toward greater protection and recognition of western IP rights. A particular area of concern has been in pharmaceuticals, as India is said to be the world's top supplier of affordable generic versions of drugs under patent that otherwise would be out of reach for millions of poor patients. Several activists have raised alarm over a meeting this week of US IP industry representatives with top judges in India.
The World Health Organization Pandemic Influenza Preparedness (PIP) Framework is at risk due to some companies not fulfilling their obligations, a new WHO report says.
The African Regional Intellectual Property Organization (ARIPO), with the help of the United States and an international plant variety organisation, is working to grow regional support for a controversial draft law. The draft protocol would boost protection for new plant varieties, despite concerns of local civil society that it would not be in the best interest of ARIPO members’ food security due to its potential impact on small farmers. ARIPO held a regional workshop on the issue in recent weeks in part to build support for a treaty negotiation to lock in these protections.
Once again, differences over the role of a World Intellectual Property Organization committee last week came in the way of consensus and prevented delegates from agreeing on future work. At the heart of the discontent was the perceived imbalance of the proposed programme of work, which some said disregarded the interests of developing countries. A speaker for the African region gave a striking speech on the Ebola crisis as an example of the failure of the patent system.
NEW YORK - Strong intellectual property rights will be a top priority for the pharmaceutical industry internationally in the coming year and arguments over IPRs versus medicines access are false, a top representative said at a high-level industry event this week. But views at the event differed on expectations of industry in light of the Ebola crisis, hepatitis C drug costs or other medicines access questions.
A high-level meeting convened by the World Health Organization yesterday on the issue of access to and financing of Ebola vaccines resulted in a set of commitments, though not with sufficient urgency for those working on the ground. The pharmaceutical industry committed to scale up production, while donors pledged funds without disclosing how deep their pockets might be.